The recent tragic deaths of two teenagers in Kent due to a Meningitis B (menB) outbreak have brought into sharp focus a critical ethical and financial dilemma within the National Health Service (NHS): the balance between clinical effectiveness and cost-effectiveness. These young lives, it is argued, might have been saved had they been vaccinated, yet the menB vaccine is not routinely offered to children born before 2015, a decision rooted in cost.

While the menB vaccine does not guarantee complete protection, it significantly reduces the risk of contracting the infection, and crucially, lessens the severity of the illness, the risk of death, and devastating complications such as limb loss, brain damage, and hearing loss. The uncomfortable truth is that this vaccine has been administered to babies since 2015, but older children remain unprotected unless their parents bear the private cost of the jab, which can exceed £200 for a full course.

This disparity forces us to confront a profound question: how much is a human life worth? In the UK, this complex decision largely falls to the National Institute for Health and Care Excellence (NICE). NICE's process involves a two-fold evaluation. Firstly, it assesses the efficacy and safety of a treatment, test, or vaccine. Secondly, it considers the more 'brutal' question: is it worth the cost? To answer this, NICE utilizes a metric called a Quality-Adjusted Life Year (QALY), where one QALY represents an extra year of life lived in good health. The system typically works on a threshold where treatments costing more than approximately £30,000 per QALY for one patient are often not funded, effectively setting a quiet price on a year of healthy existence.

While this approach is understandable given the NHS's finite budget – without such decisions, the system would be unsustainable – its practical application can become deeply problematic when considering individual patients. A vivid example is the case of a teenager treated in A&E who rapidly became critically ill with sepsis caused by menB. Despite prompt antibiotic treatment and weeks in intensive care, he tragically required the amputation of one of his legs due to compromised blood flow, a frequent complication of meningococcal septicaemia. Clinically, vaccinating him would have made perfect sense, preventing his severe illness. However, from the NHS's cost-effectiveness perspective, it wasn't deemed viable, primarily because menB is rare in teenagers, affecting only one or two per 100,000 annually. Yet, his subsequent care incurred costs reaching hundreds of thousands of pounds.

This stark contrast highlights the inherent discomfort in applying rigid cost-effectiveness logic when the potential outcomes involve life-changing disability or death, particularly in young people. The calculation NICE undertakes in such scenarios becomes ethically challenging, a tension actively campaigned against by charities like Meningitis Now, who advocate for broader menB vaccination access that is not contingent on a family's ability to pay.

The dilemma extends beyond meningitis B. It is echoed in areas like cancer care, autoimmune conditions such as rheumatoid arthritis, and the newer weight-loss jabs, where demonstrably beneficial drugs face restrictions due to their high cost per QALY. From a doctor's perspective, the primary concern is clinical effectiveness. If a treatment is effective and its benefits outweigh the risks, a doctor can discuss private payment options with patients if the NHS does not cover it. For instance, medical professionals often recommend that parents of 15- to 24-year-olds consider private menB vaccination, as this age group faces heightened risk, especially during the first year of university where close living conditions facilitate bacterial spread.

Increasingly, individuals are exploring options outside the NHS to manage their personal health risks. Julia Halpin, who manages the Being Well private pharmacy in Hove, East Sussex, observes a clear shift: "Increasingly, our patients want to take charge of their own health – and that means wanting to access medicines or services that aren't available on the NHS." This trend is evident in the growing numbers paying privately for flu vaccines and Covid boosters, acknowledging their role in reducing individual risks, including long Covid. Pharmacies are reportedly experiencing shortages of the menB vaccine as public awareness of the risks grows.

Similar personal decisions are made regarding other vaccines. For instance, the shingles vaccine is offered by the NHS to those turning 65 or aged 70-79, aligning with its most cost-effective application. However, the vaccine remains effective for other age groups (licensed from 50) and can prevent severe infection, chronic nerve pain, and vision loss, with emerging evidence even suggesting a reduced risk of dementia. Thus, an individual might choose to pay the £500 for two doses to receive it earlier. The chickenpox vaccine, routinely administered in many countries, was only introduced into the UK's childhood schedule this year, previously restricted due to cost-effectiveness, despite its potential to prevent severe complications. These examples illustrate the rational choices individuals make to mitigate personal health risks, even when they diverge from population-level cost-effectiveness decisions.

NICE's decisions are not immutable; if a menB outbreak were to widen significantly, it could shift the cost-effectiveness calculation and lead to a change in NHS policy. However, this latest outbreak has starkly illuminated the often-unexplained divergence between what is clinically effective and what is deemed cost-effective by the NHS. As more people take proactive steps, often through private means, to reduce personal health risks that the NHS cannot fund at scale, it becomes crucial for individuals to understand both clinical effectiveness and cost-effectiveness. Viewing preventative healthcare as an 'insurance policy' empowers individuals and families to make informed choices for their well-being, rather than simply accepting decisions based solely on population-level economic considerations.